Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”

Vito Lorusso, Simona Vallarelli, Francesco Giotta


Endometrial cancer is the fifth cause of cancer in women, with an incidence rate of more than 300,000 new cases per year worldwide (1). In USA it is the most common gynecologic malignancy, with approximately 61,880 newly diagnosed cases and 12,160 deaths expected in 2019 (2). Most cases are diagnosed at an early stage and have relatively good survival rates; however, women diagnosed with recurrent disease or advanced stages have a very poor prognosis (3). The standard treatment of endometrial carcinoma is hysterectomy plus bilateral salpingo-oophorectomy.